What is the purpose of this trial?
The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Ages: 60 - 75 years
Dates: 08/03/2016 - 08/31/2023
Last Updated: 01/19/2017
Study HIC#: 1601017111